Journal of Market Access & Health Policy, Volume 14, Issue 4

Effective pharmaceutical inventory management supports drug availability, financial sustainability, and patient safety. This study presents preliminary operational evaluation of an Integrated Hospital Pharmacy Inventory Management System (IHPIMS) com...

Introduction: Although the high cost of dialysis therapy can be an economic burden, peritoneal dialysis (PD) accounts for approximately 3% of the dialysis population. Studies comparing medical costs of PD and hemodialysis (HD) in Japan are limited. W...

Introduction: Medicine prices change over the product life cycle, especially around loss of exclusivity (LoE), yet economic evaluations often assume constant prices, which may bias cost-effectiveness and budget impact estimates. Methods: We developed...

Equity plays a key role in public administration, with social equity important for achieving equitable outcomes. In oncology, the sustainability of the system is a major concern, as rising prices of cancer medicines have increased spending on cancer...

The European Union (EU) Health Technology Assessment Regulation (HTAR) centralizes clinical evaluation of new health technologies via joint clinical assessment (JCA). At its core, HTAR aims to promote more equal and timely access to evidence-based he...

Generative artificial intelligence (GenAI) may assist evidence-informed health-policy work, but favorable user perceptions and well-written outputs do not establish factual reliability or implementation readiness. A multilevel mixed-methods pilot eva...

Although new cancer treatment modalities such as cellular therapies and radiopharmaceuticals have proven to be potentially transformative treatment options, there remain shortcomings with their equitable implementation in routine clinical practice ac...

Overall Comments [...]

We read with interest the cost-effectiveness analysis by Värendh et al [...]

Hemophilia A management in the United Arab Emirates (UAE) is still largely driven by treatment acquisition costs. This may limit access to innovative therapies such as emicizumab despite their broader clinical value. This paper aimed to identify barr...